At the J.P. Morgan Health Care conference this week in San Francisco, drugmakers had their sights set on the next generation ...

There's no doubt that Roche is playing catchup in the category, one of a lengthening list of pharma companies ... a once-daily formulation of its oral GLP-1 drug danuglipron as its preferred ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

Weight loss is a highly personal journey. Just as there is no one reason for wanting to lose weight, there is also no ...

Glucagon-like peptide-1 (GLP-1) medications are doing more than transforming waistlines and blood sugar levels — they're redefining corporate culture. As employers grapple with including GLP-1s in ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

The report by GlobalData, a data and analytics company, showed that anti-obesity medications are the industry trend that will ...

The terms of the IPO were not disclosed in the filing. Strong equity markets, falling interest rates and hopes of a ...

Obesity management drugs are evolving from once-weekly GLP-1 receptor agonist injections to longer-acting candidates, ...

Please provide your email address to receive an email when new articles are posted on . Those who received GLP-1s experienced decreased absolute and relative weight loss vs. placebo across 26 ...

Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...